The selective vulnerability of specific brain receptors may explain why some children with Rett syndrome experience more devastating developmental regression than others. This finding opens new precision medicine approaches for a condition that affects approximately 1 in 10,000 girls worldwide. Researchers analyzed brain tissue from Rett syndrome patients and discovered that metabotropic glutamate receptor 7 (mGlu7) expression drops significantly, but only in patients carrying severe MECP2 gene mutations. Those with milder mutations showed normal mGlu7 levels, despite both groups having the same underlying genetic disorder. Importantly, two related receptors (mGlu4 and mGlu8) remained unaffected across all patients, suggesting mGlu7 plays a uniquely critical role in severe disease progression. The team demonstrated that a positive allosteric modulator targeting mGlu7 could reverse cognitive, social, and breathing deficits in mouse models, even when the underlying genetic defect remained intact. This challenges the conventional assumption that genetic disorders require gene therapy to achieve meaningful clinical benefit. The receptor-specific pattern provides a biological explanation for Rett syndrome's variable severity and suggests clinicians could potentially stratify patients based on mutation type to predict treatment response. However, the research remains in early stages, with efficacy demonstrated only in animal models. The approach represents a shift from attempting to fix the root genetic cause toward compensating for its downstream effects through targeted neuromodulation.